Creative Biolabs Prepares Various Customized Payload-linker Complexes for Antibody-drug Development

Equipped with the exclusive “DrugLnk” organic synthesis platform, Creative Biolabs is capable of providing global clients, either academic or industrial, with a variety of customized payload-linker complexes using toxins in the Drug Module for antibody-drug conjugates development.

Shirley, United States – December 30, 2019 /MarketersMedia/ —

Emerged as the most promising next-generation targeted anti-tumor agents, antibody-drug conjugates (ADCs), consisting of monoclonal antibodies, payloads, and chemical linkers, have made a series of impressive achievements in the treatment of different diseases, especially cancers. For the sake of specific clients’ requirements on their ADC projects, Creative Biolabs has developed a professional “DrugLnk” organic synthesis platform to prepare novel payload-linker complexes.

ADC payloads from Creative Biolabs exert extremely high cytotoxic efficacy and adequate plasma stability to maintain drug efficacy before reaching the target, with a small size to reduce immunogenicity.

1.Microtubule Toxins

Microtubule toxins, featured by an excellent ability to inhibit tumor cell growth and promote apoptosis, are widely used against malignancies. A full list of microtubule toxins, including maytansinoids, auristatins, epothilone, taxoids, tubulysins, and vinorelbine, are provided by Creative Biolabs as ADC payloads with suitable linkers and conjugation strategies.

2.DNA Toxins
With the ability to induce DNA damage and subsequent cell death, DNA Toxins, which are highly toxic, are prepared with in vitro potency down to the picomolar level against tumor cell lines. Experts at Creative Biolabs are skilled at using various DNA toxins for ADC services including duocarmycins and analogs, calicheamicins, PBD-dimers, doxorubicin, topotecan, bleomycin A2, dactinomycin, and mitomycin C.

3.Transcription Toxins
Transcription toxins are another type of candidates for developing ADC, such as amatoxins, thailanstatin A, which are all available at Creative Biolabs. Currently, toxins against RNA polymerase II (the initial step in DNA transcription) and spliceosome (for correct mRNA maturation and processing) are being actively exploited.

“Based on our exclusive DrugLnk platform, we not only can prepare the above-mentioned toxins for drug antibody conjugates, but also are able to provide small molecule inhibitors, Nano-carriers, protein toxins, and toxic proteins for antibody-directed enzyme prodrug therapy (ADEPT).” Introduced by the scientist at Creative Biolabs.

Supported by a comprehensive one-stop ADC development platform, Creative Biolabs also provides a variety of ADC toxin products and Drug-linker complex products. More information can be reached at https://www.creative-biolabs.com/adc.

About Creative Biolabs
With more than a decade of exploration and expansion, Creative Biolabs provides current research and service capacity that covers the entire new drug discovery and development pipeline, ranging from early discovery, pre-clinical evaluations, cGMP manufacturing, to clinical trials. As an international cooperation, Creative Biolabs established offices all around the globe with more than 200 well-trained full-time scientists and technicians, who work closely with customers and research partners to develop new medicines for a better, healthier world. After years of pursuit for perfection, Creative Biolabs has established leadership in targeted immunotherapy and antibody-drug conjugate (ADC) development. They offer customers comprehensive one-stop-shop of all aspects in ADC research and evaluation, ranging from antigen selection, antibody production/optimization, payload-linker synthesis, ADC conjugation, to various stages of ADC characterization and pre-clinical evaluation.

Contact Info:
Name: Candy Swift
Email: Send Email
Organization: Creative Biolabs
Website: https://www.creative-biolabs.com/adc/antibody-drug-conjugate-adc.htm

Source URL: https://marketersmedia.com/creative-biolabs-prepares-various-customized-payload-linker-complexes-for-antibody-drug-development/88941099

Source: MarketersMedia

Release ID: 88941099

Go Top